Cancel
OK

You have successfully logged out.

Hello !
chevron_right My profile
chevron_right To My B. Braun overview
Logout

Askina® Calgitrol®

Advanced Wound Care

The B. Braun Askina Calgitrol range are silver antimicrobial dressings, designed to provide sustained and conformable treatment for infected wounds in the NHS.

Infected Wounds

Wound infections can compromise the healing process, with significant negative impacts on health-relating quality of life. [1] [2]​

Infected wounds cause a considerable burden to the healthcare system, bear the risk of amputation and sepsis,[3] while delaying wound healing.​

It is important to find the best strategy to prevent, diagnose and manage wound infections.

  • More than

    0%

    of chronic wounds are estimated to be infected.[4,5]

Chronic wounds

Prevention and treatment of wound infection

The wound infection continuum looks at the different stages of wound infection, progressing from initial contamination up to sepsis,[6] [7] which can support the best strategy to prevent diagnose and manage wound infection.

Manage infected wounds covering all stages of the wound infection continuum 

Graphic showing all stages of the wound infection continuum and treatment mit Prontosan and Askina Calgitrol

Choose a dressing based on ​
wound and patient needs


Silver dressings are available in different forms. The choice of dressing depends on the wound and patient, e.g. exudate levels, wound depth, need for conformability, odour control, ease of removal and safety.

Askina® Calgitrol® Paste

A silver alginate paste. Highly conformable, not only for small tunnels and sinuses, but suitable for all wound types like Diabetic Foot Ulcers (DFU) and Venous Leg Ulcers (VLU).

Askina® Calgitrol® Ag+

An antimicrobial silver dressing combined with reinforced fiber, for superficial highly exuding wounds.

Experience B. Braun Askina® Calgitrol® for yourself:


Request your free NHS antimicrobial sample pack today and discover the impact of B. Braun's wound infection control.

Samples

Find out more

Antimicrobial Dressings

Askina® Calgitrol® Paste

Askina® Calgitrol® Paste is a sterile primary dressing consisting of an ionic silver alginate matrix in paste form, designed to treat chronic wounds which are infected or at high risk of infection.   The paste form, due to its water content, provides immediate availability of silver ions. Additionally, the ionic exchange with the wound exudate, delivers a sustained release of ionic silver to the wound bed.1   It is supplied sterile in a 15 g tube. The tube has a cannula to aid application of the paste into tunnels, sinuses, and all deep wounds. 2

Askina® Calgitrol® Ag+

Askina® Calgitrol® Ag+ is a wound dressing that combines antimicrobial silver with strengthening cellulose fiber to manage wound infection and high exudate. The dressing promotes healing in a moist environment.  When applied, Askina® Calgitrol® Ag+ responds by forming a gel on contact with wound exudate. The gelling formation traps, locks in and kills the bacteria away from the wound bed. It contains encapsulated nanoparticles of ionic silver encrusted into the strengthening cellulose fiber. The nanoparticles act as a reservoir of ionic silver and are released gradually in contact with wound fluid to kill bacteria and microorganisms within the dressing.Under the supervision of a healthcare professional, Askina® Calgitrol® Ag+ antimicrobial wound dressings may be used for:All agesModerately to heavily exuding woundsChronic wounds, e. g. leg ulcers, pressure ulcers and diabetic ulcersSurgical wounds, e. g. post-operative, wounds left to heal by secondary intent and donor sitesTraumatic wounds, e. g. abrasions and lacerationsPartial thickness burnsIf required, the dressings can be used in conjunction with a suitable moisture-retaining secondary dressing to keep the product in place and/or under compression.

Related Documents

References

 
  1. Phillips CJ, Humphreys I, Fletcher J, Harding K, Chamberlain G, Macey S. Estimating the costs associated with the management of patients with chronic wounds using linked routine data. Int Wound J. 2016 Dec;13(6):1193-1197. doi: 10.1111/iwj.12443. Epub 2015 Mar 26. PMID: 25818405; PMCID: PMC7949824.
  2. Purwins S, Herberger K, Debus ES, Rustenbach SJ, Pelzer P, Rabe E, Schäfer E, Stadler R, Augustin M. Cost-of-illness of chronic leg ulcers in Germany. Int Wound J. 2010 Apr;7(2):97-102. doi: 10.1111/j.1742-481X.2010.00660.x. PMID: 20529149; PMCID: PMC7951196.
  3. Yammine K, El Alam A, Alqaysi B, Assi C. The internal pedal amputation as a salvage procedure in diabetic and ischemic foot infection. A meta-analysis. Foot Ankle Surg. 2022 Feb;28(2):159-165. doi: 10.1016/j.fas.2021.03.008. Epub 2021 Mar 16. PMID: 33752981
  4. Reitan RL, McBroom RM, Gilder RE. The Risk of Infection and Indication of Systemic Antibiotics in Chronic Wounds. Wounds. 2020 Jul;32(7):186-194. PMID: 33166266.
  5. Schollemann F, Kunczik J, Dohmeier H, Pereira CB, Follmann A, Czaplik M. Infection Probability Index: Implementation of an Automated Chronic Wound Infection Marker. J Clin Med. 2021 Dec 29;11(1):169. doi: 10.3390/jcm11010169. PMID: 35011910; PMCID: PMC8745914
  6. Kingsley A. The wound infection continuum and its application to clinical practice. Ostomy Wound Manage. 2003 Jul;49(7A Suppl):1-7. PMID: 12883156.
  7. Deeth M. A closer look at the wound infection continuum. Br J Community Nurs. 2017 Dec 1;22(Sup12):S48-S50. doi: 10.12968/bjcn.2017.22.Sup12.S48. PMID: 29189070.